Quick Read Citigroup's Geoff Meacham targets $1,600 for LLY, representing 37% upside, anchored by Mounjaro and Zepbound's combined $14.9B single-quarter revenue. Novo Nordisk dropped 8% in one session after its post-Wegovy update disappointed, while Viking Therapeutics carries 207% implied upside on clinical-stage binary risk. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut. Eli Lilly (NYSE:LLY) currently trades at $1,164.79, while Wall Street's average analyst price target sits at $1,325.39.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。